Kurs
-2,50%
Likviditet
0,18 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-05-07 | N/A | Årsstämma |
2026-05-07 | 08:30 | Kvartalsrapport 2026-Q1 |
2026-02-20 | 08:30 | Bokslutskommuniké 2025 |
2025-10-30 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-10-10 | N/A | Extra Bolagsstämma 2025 |
2025-08-11 | - | Kvartalsrapport 2025-Q2 |
2025-05-08 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2025-05-07 | - | Årsstämma |
2025-05-07 | - | Kvartalsrapport 2025-Q1 |
2025-02-20 | - | Bokslutskommuniké 2024 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2024-05-07 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-10-31 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2023-05-25 | - | Årsstämma |
2023-05-03 | - | Kvartalsrapport 2023-Q1 |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-11-02 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-30 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2022-05-27 | - | Årsstämma |
2022-05-06 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-24 | - | Extra Bolagsstämma 2021 |
2021-10-20 | - | Kvartalsrapport 2021-Q3 |
2021-08-18 | - | Kvartalsrapport 2021-Q2 |
2021-05-28 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2021-05-27 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-03 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-28 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2020-05-27 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-17 | - | Bokslutskommuniké 2019 |
2019-10-31 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-06-04 | - | Årsstämma |
2019-05-23 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
2019-04-30 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
Beskrivning
Land | Sverige |
---|---|
Lista | Nordic SME Sweden |
Sektor | Hälsovård |
Industri | Medicinteknik |
Lumito, a leading medical technology company focused on tissue analysis, is launching a new website today, centered around the core message: "Increasing objectivity in tissue analysis."
"Our new website is a direct result of insights gathered from users and partners," says CEO Sanna Wallenborg. “There has been a clear need to better clarify and deepen the understanding of the key benefits of our technology, as well as to provide examples of application areas. We are now presenting this in a more accessible and comprehensive format – specifically tailored to audiences in pharma development and research. The website launch marks a step toward establishing Lumito as a player in advanced tissue analysis, and we have received very positive feedback from the partners we engaged with during the process."
Visit the new website at www.lumito.se
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/